Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoroquinolone Added to Standard Triple Therapy in Disseminated MAC Infection
NCT07585461Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
01
Overview
Randomised, open-label trial of levofloxacin and moxifloxacin in Mycobacterium avium complex infection (MAC) (2 arms). Primary endpoint: Clinical Symptom Resolution Rate at Day 28. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
levofloxacinmoxifloxacin
03
Conditions
Mycobacterium avium complex infection (MAC)
Beyond the preview
Go deeper on NCT07585461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585461.